Latest News

Mecasermin treatment for Rett Syndrome is safe, well-tolerated

A Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)] has been completed for Rett Syndrome research, showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
View full story

Post your comment.


  • Trust your aha! moments: Experiments show they're probably right

  • Scientists use synthetic gene and magnets to alter behavior of mice, fish

  • Teen girls see big drop in chemical exposure with switch in cosmetics

  • Female traders can reduce market crashes, expert says

  • Toxic byproduct of hemoglobin could provide clues for cerebral hemorrhage and Creutzfeldt-Jakob Disease

  • Clinician communication reduced distress related to the detection of incidental nodules

  • Talk about yourself on social media?

  • New mothers with postpartum psychiatric disorders face increased risk of suicide, study shows

  • Combining two techniques to 'rewire' the brain may improve arm, hand movement for stroke survivors

  • Scientists map roots of premeditated, violent 'intent' in animal brain